newsfilter
← Latest News
ClinicalTrials.gov·

Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria - NCT05314231

Serum Concentration of ALXN1720, Number of Participants With Treatment-Emergent Adverse Events, Serum Concentration of Free and Total Complement Component 5 (C5), Number of Participants With Antidrug Antibodies (ADAs) to ALXN1720